Literature DB >> 21263434

Type 2 diabetes mellitus in 2010: individualizing treatment targets in diabetes care.

John B Buse1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21263434     DOI： 10.1038/nrendo.2010.230

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  8 in total

1.  Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis.

Authors:  Richard Kahn; Peter Alperin; David Eddy; Knut Borch-Johnsen; John Buse; Justin Feigelman; Edward Gregg; Rury R Holman; M Sue Kirkman; Michael Stern; Jaakko Tuomilehto; Nick J Wareham
Journal:  Lancet       Date:  2010-03-29       Impact factor: 79.321

2.  Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

Authors:  Faramarz Ismail-Beigi; Timothy Craven; Mary Ann Banerji; Jan Basile; Jorge Calles; Robert M Cohen; Robert Cuddihy; William C Cushman; Saul Genuth; Richard H Grimm; Bruce P Hamilton; Byron Hoogwerf; Diane Karl; Lois Katz; Armand Krikorian; Patrick O'Connor; Rodica Pop-Busui; Ulrich Schubart; Debra Simmons; Harris Taylor; Abraham Thomas; Daniel Weiss; Irene Hramiak
Journal:  Lancet       Date:  2010-06-30       Impact factor: 79.321

3.  Effects of medical therapies on retinopathy progression in type 2 diabetes.

Authors:  Emily Y Chew; Walter T Ambrosius; Matthew D Davis; Ronald P Danis; Sapna Gangaputra; Craig M Greven; Larry Hubbard; Barbara A Esser; James F Lovato; Letitia H Perdue; David C Goff; William C Cushman; Henry N Ginsberg; Marshall B Elam; Saul Genuth; Hertzel C Gerstein; Ulrich Schubart; Lawrence J Fine
Journal:  N Engl J Med       Date:  2010-06-29       Impact factor: 91.245

4.  Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.

Authors:  John B Buse; Richard M Bergenstal; Leonard C Glass; Cory R Heilmann; Michelle S Lewis; Anita Y M Kwan; Byron J Hoogwerf; Julio Rosenstock
Journal:  Ann Intern Med       Date:  2010-12-06       Impact factor: 25.391

5.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

6.  Effects of combination lipid therapy in type 2 diabetes mellitus.

Authors:  Henry N Ginsberg; Marshall B Elam; Laura C Lovato; John R Crouse; Lawrence A Leiter; Peter Linz; William T Friedewald; John B Buse; Hertzel C Gerstein; Jeffrey Probstfield; Richard H Grimm; Faramarz Ismail-Beigi; J Thomas Bigger; David C Goff; William C Cushman; Denise G Simons-Morton; Robert P Byington
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

7.  Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial.

Authors:  Matthew C Riddle; Walter T Ambrosius; David J Brillon; John B Buse; Robert P Byington; Robert M Cohen; David C Goff; Saul Malozowski; Karen L Margolis; Jeffrey L Probstfield; Adrian Schnall; Elizabeth R Seaquist
Journal:  Diabetes Care       Date:  2010-05       Impact factor: 19.112

8.  Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association.

Authors:  Jay S Skyler; Richard Bergenstal; Robert O Bonow; John Buse; Prakash Deedwania; Edwin A M Gale; Barbara V Howard; M Sue Kirkman; Mikhail Kosiborod; Peter Reaven; Robert S Sherwin
Journal:  Diabetes Care       Date:  2008-12-17       Impact factor: 17.152
  8 in total
  4 in total

1.  Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews
Journal:  Diabetologia       Date:  2012-04-20       Impact factor: 10.122

Review 2.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112

3.  Genipin inhibits mitochondrial uncoupling protein 2 expression and ameliorates podocyte injury in diabetic mice.

Authors:  Wenjing Qiu; Yang Zhou; Lei Jiang; Li Fang; Lu Chen; Weifang Su; Ruoyun Tan; Chen-yu Zhang; Xiao Han; Junwei Yang
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

4.  Enhancement of glucose homeostasis through the PI3K/Akt signaling pathway by dietary with Agaricus blazei Murrill in STZ-induced diabetic rats.

Authors:  Qi Wei; Jie Li; Yishu Zhan; Qiangui Zhong; Baogui Xie; Lei Chen; Bingzhi Chen; Yuji Jiang
Journal:  Food Sci Nutr       Date:  2020-01-13       Impact factor: 2.863
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.